Mixed connective tissue disease (MCTD) was first described in 1972 as a disease syndrome with overlapping features of systemic sclerosis, systemic lupus erythematosus (SLE) and polymyositis associated with antibodies to RNAse sensitive extractable nuclear antigen. When the antigen was subsequently characterized as polypeptides on the U1 ribonuclear protein component of the splicesosome (U1RNP), MCTD became the first rheumatic disease syndrome to be defined by a serologic test. Clinical features include a high frequency of Raynaud's syndrome, swollen hands, sclerodactyly, arthritis, polymyositis and interstitial lung disease. Over the last 30 years there has been a continuing debate as to whether MCTD constitutes a 'distinct clinical entity'. Here, I will review the pathological, immunogenetic and clinical features of MCTD and conclude that the debate remains unresolved. The early misconception that it has a relatively good prognosis has not stood the test of time with long-term follow-up studies. These have identified a tendency for MCTD to evolve into SLE or systemic sclerosis and highlighted pulmonary hypertension and scleroderma renal crisis as important causes of death. Providing it is realized that our appreciation of the clinical features associated with anti-U1RNP have evolved over time, MCTD remains a useful concept in clinical practice. Whether it can be credited with the term 'disease' awaits the demonstration of common etiopathological events underlying the development of antibodies to U1 RNP and their associated clinical features. Lupus (2006) 15, 132-137.
Introduction
A complete diagnosis of a disease depends on knowledge of its cause. The etiologies of all autoimmune connective tissue diseases are unknown, and diagnosis depends on patterns of symptoms, signs and laboratory investigations. The problems in rheumatology are heightened by the tendency for one disease type to merge with another leading to a continuous spectrum of clinical features among the rheumatic diseases, with the traditionally accepted entities such as systemic lupus erythematosus (SLE) or systemic sclerosis occupying only part of the continuum, with the overlap syndromes lying between. To define an overlap syndrome, it is necessary to identify a constellation of distinctive clinical or serological features that constitute a true syndrome. The majority of patients with autoimmune connective tissue diseases have non-organ-specific autoantibodies to DNA, RNA or proteins that bind to them. 1 The antigenic specificity of these antibodies has done much to justify the distinctiveness of the traditionally recognized diseases. For example, SLE is associated with the 'markers', anti-double-stranded (ds)DNA or anti-Sm. However, antibody types do not always respect tradition: many coincide with parts of the spectrum in which diseases overlap with each other. The best known example is the antibody that reacts with U1-ribonucleoprotein (RNP), which is found in patients with overlapping features of SLE, systemic sclerosis and polymyositis which has been termed mixed connective tissue disease MCTD.
History
The evolution of our concept of MCTD has depended on two factors: first, our understanding of the antigen recognized by the antibodies that define the disease and, second, by the associated clinical features (Table 1) . A complement fixation test using a saline nuclear extract, termed extractable nuclear antigen, represented the first stage in the development of the serologic test. The assay became refined to a hemagglutination test incorporating enzymatic treatment of the antigen mixture, which led to the definition of MCTD as a diagnostic entity associated with antibodies to the ribonuclease (RNase)-sensitive fraction of extractable nuclear antigen. 2 It was claimed that MCTD could be distinguished from SLE on the basis that SLE sera reacted with the RNase-resistant component. The RNase-resistant component was subsequently characterized as the previously described Sm antigen and the RNase-sensitive component as a nuclear ribonuclear protein, which was simply termed 'RNP' or 'nRNP'. 3 Further definition of the RNP and Sm antigens awaited the use of immunoprecipitation of [ 32 P]labelled cells, which showed, surprisingly, that both Sm and RNP were ribonucleoproteins. 4 The RNP antigen resided on polypeptides bound to the U1 (uridine-rich) RNP complex, whereas the Sm antigen was present on U1, U2, U4, U5 and U6 complexes. Analysis by immunoblotting showed that the major epitopes recognized by MCTD sera were a 68 kDa polypeptide bound to U1-RNA, and those for anti-Sm antibodies were a 28 kDa doublet and a 16 kDa polypeptide. For this reason, the RNP antigen changed its name yet again, to U1-RNP, although Sm has retained its original name.
Epidemiology
The prevalence of MCTD is unknown. In most studies, the number of patients with clinical and serologic features of the syndrome are about four-fold fewer than patients with SLE, suggesting an overall prevalence in the region of 10/100 000. The female : male ratio is about 9 : 1 and the disease does not appear to show the relative preponderance of Afro-Caribbeans seen in SLE. No particular environmental agents have been associated with the disease, although it is of interest that occupational exposure to vinyl chloride has been described. 5 Several studies have described an association with DR4, one suggesting that the link could be accounted for by those MCTD patients who had erosive arthritis. 9 A significantly increased frequency of the immunoglobulin allotypes Gm1.3 and 3 have also been described. 6 
Clinical features
Being an overlap syndrome, MCTD lacks any distinctive clinical features ( Table 2 ). Raynaud's phenomenon is very common, and is often associated with oedema of the hands. This feature is often (wrongly) regarded as peculiar to MCTD; swollen hands also occur in early scleroderma, eosinophilic fasciitis and the anti-tRNA (tRNA) synthetase antibody associated overlap syndromes. Arthritis and arthralgias are also common, but again lack any unique pattern. 7 Joint disease ranging from a relatively mild SLE-like peripheral synovitis through to erosive disease typical of RA, and even arthritis mutilans, has been described. 7 Myositis, fibrosing alveolitis and pulmonary hypertension are the most important common features of the syndrome. There is little evidence to suggest that the pattern of muscle or lung involvement in MCTD differs from that of other diseases, although studies of patients selected purely on the basis of myositis or fibrosing alveolitis suggest that the prognosis in patients with anti-U1-RNP may be marginally better than in those without. 8 Nevertheless, both myositis and fibrosing alveolitis are potentially fatal, and pulmonary hypertension, in particular, is a lethal complication. Some studies (reviewed by Hoffman and Greidinger 9 ) have suggested that pulmonary hypertension may be associated with coexistent antiphospholipid antibodies. More importantly, the pulmonary artery pressure decreases with prostacycline infusions or treatment with immunosuppressive drugs. 9 Other clinical features of MCTD simply reflect those of the diseases that it overlaps. Skin manifestations include sclerodactyly, scleroderma (usually relatively restricted), calcinosis, telangiectasia, photosensitivity, malar rash and the rash of dermatomyositis. Pleurisy and pericarditis occur in about 60% of patients. Radiologic evidence of esophageal dysmotility has long been recognized as a feature in more than 50% of patients. Gastrointestinal manifestations include a high frequency of heartburn (48%) and dysphagia (38%) in patients with MCTD, and more rarely, malabsorption syndromes and bowel perforations as a result of vasculitis. 10 Sjögren's syndrome occurs in about 50% of patients with MCTD, although the sicca symptoms are usually less prominent than in those with anti-La(SS-B) antibodies. Trigeminal neuralgia, although a recognized feature of SLE, is a striking feature of MCTD in about 25% of cases.
When first described, MCTD was believed to be characterized by good prognosis and a low frequency of cerebral and renal disease (compared with SLE). This opinion has now been revised, after longer follow-up studies, to the view that the prognosis in MCTD is in fact worse than that in lupus, most of the deaths being attributable to pulmonary hypertension. 11 When renal involvement occurs, it is either membranous nephritis or, less commonly, the renal vasculopathy characteristic of scleroderma, leading to malignant hypertension.
Investigations
The diagnosis of MCTD is critically dependent on the demonstration of high-titer anti-U1-RNP antibodies. In early studies, the hemagglutination assay was most commonly performed, although this test is subject to the criticism that the antigen mixture coating the red cells contained more than one RNase-sensitive antigen. For this reason, it is preferable to demonstrate the antibody by immunodiffusion, either passive double diffusion or counterimmunoelectrophoresis, with the antibody specificity confirmed by a precipitin line of immunologic identity with a reference serum. It is also possible to define the antibody by immunoblotting or immunoprecipitation of [ 32 P]-labelled cell extracts, although these assays suffer from being rather cumbersome and, at best, only semiquantitative. The use of purified or cloned antigens in quantitative enzymelinked immunosorbent assay are currently the preferred assays in most laboratories. One of the difficulties in serologic diagnosis of MCTD is that most attempts at diagnostic criteria specify a 'high titre'. Although cut-off points of 1:1000 or 1:1600 have been suggested for the hemagglutination test, there has yet to be a defined limit for other assays in more frequent use. The presence of anti-U1-RNP antibodies in the serum means that all MCTD sera will give a speckled nuclear staining pattern on indirect immunofluorescence. Unfortunately, the usefulness of this test is limited by the fact that other autoantibodies, notably anti-Sm and anti-La(SS-B), give very similar staining patterns.
Other investigations show features common to connective tissue diseases in general. The most frequent hematologic findings are leukopenia, thrombocytopenia and a high erythrocyte sedimentation rate. Serum immunoglobulins may be extremely high, with IgG concentrations reaching more than 40 g/L in some patients. In contrast to SLE, in MCTD the complement concentrations are usually normal or high. Rheumatoid factors are increased in approximately 70% of patients. Important negative findings are tests for anti-Sm and anti-DNA antibodies. These, if present, in the opinion of Sharp et al., 3 represent exclusion criteria for the diagnosis of MCTD, and suggest that the disease lies more firmly in the SLE part of the spectrum.
Structure and function of the U1-RNP particle
One justification for defining a disease by a serologic test is based on the assumption that anti-U1-RNP and its antigen are intrinsically involved in the pathogenesis of the disease. Although there is no direct evidence to support it, it is a valid hypothesis worthy of investigation.
The U1 RNP particle is one of a series of uridinerich RNA particles that are involved in the splicing of messenger RNAs (mRNA). It is composed of eight polypeptides linked to RNA, of which two, 68 kDa and 33 kDa, carry the epitopes recognized by MCTD sera. The other polypeptides, principally 28 kDa and 16 kDa, react with anti-Sm antibodies. The presence of both U1-RNP and Sm epitopes on the same molecular complex, together with the frequent coexistence of the two antibody specificities, is often taken as evidence for antigen drive by the entire molecular complex. A similar association between the Ro and La antigens (on the hY RNAs) has been proposed as a mechanism for the induction of anti-Ro and anti-La, which also tend to occur together.
Aetiology
If the current concept of autoantigen drive is accepted, it is necessary to explain how an intranuclear protein becomes available to the immune system. Such a mechanism could be the expression of intracellular ribonucleoproteins on the cell surface in apoptotic blebs. 12 Tolerance breakdown could then occur as a result of post-translational modification of the 70 kDa Mixed connective tissue disease PJW Venables molecule 13 or, conceivably, as a result of molecular mimicry with viral antigens. This has been proposed on the basis of sequence similarities between the 33 kDa polypeptide of U1-RNP and a consensus sequence common to a number of animal retroviruses. Infection with a similar exogenous virus or expression of an endogenous retrovirus that is not normally exposed to the immune system could result in the induction of autoantibodies to U1-RNP by molecular mimicry. 14 
Management
There is no specific treatment for MCTD. One of the original claims in support of MCTD being a 'distinct clinical entity' was its favourable prognosis and unusual responsiveness to treatment with corticosteroids. Like others, this observation has not stood the test of time. It is now agreed that the treatment depends entirely on the pattern of clinical involvement. All patients with MCTD require careful, long-term follow-up. As in SLE, management is based on clinical assessment and laboratory tests for specific organ involvement. At each visit, every patient's clinical evaluation should include physical examination and blood pressure; laboratory tests should include full blood count, muscle enzymes and urine analysis for protein. There is no single laboratory test that can be used for monitoring disease activity and progression, although several studies have suggested that an increase in anti-U1-RNP antibodies measured by a quantitative enzyme-linked immunosorbent assay may be helpful in the short term for predicting flares of the disease. In some patients, a decrease in total white cell count (particularly the lymphocyte count) or an increase in erythrocyte sedimentation rate and total immunoglobulin concentrations may be helpful in assessing overall disease activity, although these should never be relied on for dictating treatment options. At intervals, depending on the severity of the disease, a full survey of autoantibodies, including anti-Sm and anti-dsDNA, should be performed as an early warning of those differentiating into SLE.
Pulmonary hypertension, which may or may not be associated with fibrosing alveolitis, is the most frequent cause of death directly attributable to MCTD. This should always be anticipated, by examining patients for basal rales and by performing regular chest radiographs. Because many patients with early pulmonary involvement have no abnormal physical signs and normal radiographs, it is advisable to perform pulmonary function tests and echocardigrams at presentation, and at subsequent intervals to assess progression. If there is evidence of deterioration, bronchial alveolar lavage or biopsy can be used to assess disease activity before treatment.
Drug treatment for MCTD depends on symptoms or the pattern of organ involvement. About 33% of patients have their disease adequately controlled by analgesics or non-steroidal anti-inflammatory drugs. Raynaud's phenomenon can be particularly troublesome, and is characteristically unresponsive to corticosteroids. Most patients derive some benefit from simple conservative treatment with electrically heated gloves, and a minority respond to calcium channel antagonists such as nifedipine. Severe cases respond to infusions of prostaglandin analogs. Arthritis and SLE-like skin involvement is often treated successfully with antimalarial agents such as hydroxychloroquine. There is some anecdotal evidence that patients with MCTD are liable to hypersensitivity to disease-modifying antirheumatic drugs such as sulphasalazine. Low-dose corticosteroids are effective for controlling cutaneous edema, arthritis and pleurisy; high-dose corticosteroids are indicated for the treatment of severe systemic disease such as vasculitis, myositis or fibrosing alveolitis. Myositis is a particularly important complication, requiring the correct use of corticosteroids. Because of the mistaken belief that MCTD is peculiarly corticosteroid-responsive, patients may be given inappropriately low doses. In addition, the apparent lack of an early response may drive the physician into the unnecessary use of cytotoxic drugs. Myositis in MCTD should be treated in the same way as myositis occurring in any other context. High-dose prednisolone (about 1 mg/kg per day) should be given for at least six weeks before gradual reduction of the dose to a maintenance level.
Immunosuppressive drugs are used in two contexts in MCTD: for the induction of remission or for their corticosteroid-sparing effects. The most common indication for induction of remission is fibrosing alveolitis, although any SLE-like manifestation such as nephritis or systemic vasculitis may also require immunosuppression. The most common drug used in this context is cyclophosphamide, in a daily oral dose of 1-2 mg/kg per day in combination with high-dose corticosteroids. Cyclophosphamide may also be given as pulse therapy, either as single intravenous infusions of 500 mg to 1 g spaced at intervals of two-four weeks, depending on the complete blood count, or as weekly oral pulses of 300 mg; both regimens to a total dose of 3-6 g. Controlled trials comparing these treatments are urgently needed, although the heterogeneity of the clinical expression of MCTD poses considerable problems in designing an appropriate study. Azathioprine is used mainly as a corticosteroid-sparing drug or as maintenance treatment in a dose of 2 mg/kg per day after induction of a response with cyclophosphamide. Methotrexate may be effective, although the similarity of one of its side effects to a frequent clinical feature of the disease, pulmonary fibrosis, may pose management problems. Nevertheless, it has been used successfully for the treatment of fibrosing alveolitis in patients with Jo-l antibody. 16
Is MCTD a distinct clinical entity?
The clinical features of MCTD, their relationship to antibodies to U1-RNP, and whether they constitute a distinct entity are still debated. [17] [18] [19] In general, almost all reports have confirmed the high frequency of arthritis, Raynaud's phenomenon and lung disease observed by Sharp and his colleagues. 2, 3 The only significant differences which have emerged over the last three decades is that myositis is probably much less common than the 66% originally suggested andc that the prognosis is worse than that of SLE. Arguments for and against its definition of MCTD as a separate entity are summarized as in Table 3 .
Counter to the 'against' arguments listed in Table 3 are that many of these are also applicable to accepted entities such as SLE and Sjögren's syndrome. It is also worth noting that autoantibodies are now incorporated in the diagnostic criteria for these diseases. Although the original objections to concept of MCTD remain valid, it has gained historical respectability and is a useful label for a spectrum of clinical involvement associated with an anti-U1-RNP. The importance of MCTD is not so much in terms of diagnosis, but rather what the antibody tells us about patients. Particularly important is the heterogeneity of the patterns of clinical involvement and the need to tailor treatment accordingly. The clinician must anticipate the potentially lethal complications of pulmonary hypertension, myositis and fibrosing alveolitis, and the tendency of the disease to evolve into one of its sister diseases such as SLE or systemic sclerosis. Whether MCTD can be credited with the term 'diagnosis' awaits the demonstration (or otherwise) that anti-U1-RNP antibodies and their associated clinical features are attributable to a single aetiological agent. 
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